Citation: Le. Morris et al., CHARACTERIZATION AND PERFORMANCE OF A NEW DIRECT COMPRESSION EXCIPIENT FOR CHEWABLE TABLETS - XYLITAB(R), Drug development and industrial pharmacy, 22(9-10), 1996, pp. 925-932
Citation: Le. Morris et Jb. Schwartz, ISOLATION OF DENSIFICATION REGIONS DURING POWDER COMPRESSION, Drug development and industrial pharmacy, 21(4), 1995, pp. 427-446
Citation: Le. Morris, THE USE OF THE COPPER KETTLE VAPORIZER IN CLOSED-SYSTEM CARBON-DIOXIDE ABSORPTION ANESTHESIA, Anaesthesia and intensive care, 22(4), 1994, pp. 383-386
Authors:
DEVINE SM
WINTON EF
HOLLAND HK
GELLER RB
HEFFNER LT
HILLYER CD
MORRIS LE
RODEY GE
BEVERIDGE R
LYNCH J
KLEIN L
DIX SP
WINGARD JR
Citation: Sm. Devine et al., SIMULTANEOUS ADMINISTRATION OF INTERLEUKEN-6 (RHIL-6) AND NEUPOGEN(R)(RHG-CSF) FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) FORBREAST-CANCER (BCA), Blood, 84(10), 1994, pp. 10000089-10000089
Authors:
DEVINE SM
GELLER RB
HOLLAND HK
MORRIS LE
WINTON EF
HEFFNER LT
HILLYER CD
RODEY GE
DIX SP
OTOOLE K
ROUTENBERG K
VOGLER WR
MAUER D
ARO R
FITZSIMMONS WE
WINGARD JR
Citation: Sm. Devine et al., FK506-BASED IMMUNOSUPPRESSION FOR PREVENTION OF GRAFT-VERSUS-HOST-DISEASE (GVHD) AFTER MATCHED UNRELATED DONOR (MUD) MARROW TRANSPLANTATION, Blood, 84(10), 1994, pp. 10000341-10000341
Citation: Gb. Vogelsang et Le. Morris, PREVENTION AND MANAGEMENT OF GRAFT-VERSUS-HOST DISEASE - PRACTICAL RECOMMENDATIONS, Drugs, 45(5), 1993, pp. 668-676